Retinal Diseases

40 treatments and conditions followed through the public trial records. Not medical advice. How a status is set

Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.

Narrower: Cone-Rod Dystrophies 1, Geographic Atrophy 6, Leber Congenital Amaurosis 8, Macular Degeneration 14, Retinal Degeneration 30, Retinitis Pigmentosa 14, Stargardt Disease 3, Wet Macular Degeneration 1

Treatments and conditions

Retinal Diseases
Treatment and conditionWhere it standsTrials
1.5 x 10^6 UC-MSC + CM for retinitis pigmentosaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
5 x 10^6 UC-MSC + CM for retinitis pigmentosaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
AAV2-hRPE65v2,voretigene neparvovec-rzyl for leber congenital amaurosisTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
AAV2-hRPE65v2,voretigene neparvovec-rzyl for retinitis pigmentosaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
ACDN-01 for cone-rod dystrophiesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ACDN-01 for stargardt diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ADVM-022 for wet macular degenerationPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
Autologous iPSC-derived RPE for macular degenerationTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Brinretigene Vesgedparvovec for leber congenital amaurosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Brinretigene Vesgedparvovec for retinal degenerationPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
BS01 for retinitis pigmentosaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
ER-100 epigenetic therapy for retinal diseasesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Eyecyte-RPE™ for geographic atrophyPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (RPE) for retinitis pigmentosaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Intensified medical follow-up and glucose-lowering drugs for retinal diseasesTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
NT-101 ophthalmic solution for macular degenerationPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
OCU400 High Dose for leber congenital amaurosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
OCU400 High Dose for retinitis pigmentosaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
OCU400 High Dose + OCU400 Med Dose for leber congenital amaurosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
OCU400 High Dose + OCU400 Med Dose for retinitis pigmentosaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
OCU400 Low Dose for leber congenital amaurosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
OCU400 Low Dose for retinitis pigmentosaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
OCU400 Med Dose for leber congenital amaurosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
OCU400 Med Dose for retinitis pigmentosaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
OCU400 Second Eye Dosing for leber congenital amaurosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
OCU400 Second Eye Dosing for retinitis pigmentosaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
OCU410 for geographic atrophyPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
OLN324 for macular degenerationTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
OpRegen for geographic atrophyPhase 2 trial, as of 19 Nov 2026 (not yet checked by a person)1
OpRegen for macular degenerationPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
Prima for geographic atrophyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
PRIMA Bionic Vision System for geographic atrophyTrial registered, as of 19 Nov 2026 (not yet checked by a person)2
PRIMA Products for retinitis pigmentosaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
PRIMA Products for stargardt diseaseTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
PST-611 for geographic atrophyTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
Puliretgene Parvec for retinitis pigmentosaPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
rAAV2.REP1 for retinitis pigmentosaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
RTx-015 for retinitis pigmentosaTrial registered, as of 19 Nov 2026 (not yet checked by a person)1
SB-007 for stargardt diseasePhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1
voretigene neparvovec-rzyl for leber congenital amaurosisPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)2

Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.